BACKGROUND: Very little is known about the pharmacokinetics of chemotherapeutic agents in @entity1 also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of @entity900 and @entity1487 in plasma and peritoneal dialysate in a @entity1 being treated for @entity420 . METHODS: A single @entity1 with @entity420 and on peritoneal dialysis for @entity454 was treated with @entity900 25  mg/m(2) on day 1 of weeks 1 and 5 and continuous infusional @entity1487 1000  mg/m(2)/day on days 1-4 of weeks 1 and 5 along with daily radiation therapy. Intense plasma and dialysate sampling was performed during the week 5 administration, followed by quantitation of @entity902 by atomic absorption spectrophotometry and @entity1487 by LC-MS/MS. RESULTS: Following systemic administration, clearance of ultrafilterable (active) @entity902 over the first 6  h was 20.8  L/h, which is lower than previously reported clearance levels of ultrafilterable @entity902 . Total @entity902 AUC was 131   g  h/mL, also higher than an AUC previously reported for total @entity902 in @entity1 with normal renal function. @entity902 -related material was detected in the peritoneal cavity, but this is likely inactive. @entity1487 penetrated the intraperitoneal cavity, but the contribution of peritoneal dialysis to drug clearance was negligible at 0.072  %. CONCLUSIONS: Administration of intravenous @entity900 and @entity1487 chemotherapy to a @entity1 treated with continuous ambulatory peritoneal dialysis is feasible, but clearance in dialysate is nominal, thus suggesting that dose reduction is indicated for @entity900 . Systemic drug administration results in limited intraperitoneal penetration of @entity1487 and inactive @entity902 species.

A pharmacokinetic analysis of @entity900 and XXXX in a @entity1 with esophageal cancer on peritoneal dialysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['Platinum', 'platinum'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity420 :: ('MESH:D000230', 'Disease') :: ['esophageal adenocarcinoma'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-Fluorouracil', '5-fluorouracil'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']
@entity1487 :: (MESH:D005472,Chemical) :: ['5-fluorouracil']
